Status Awaiting development
Decision None selected
Process TAG
ID number 3951

Provisional Schedule

Expected publication 14 September 2022

Project Team

Project lead Gavin Kenny

Email enquiries

Stakeholders

Companies sponsors • AbbVie (dexamethasone intravitreal implant)
Others • Department of Health and Social Care
  • NHS England
  • Welsh Government
Patient carer groups • Diabetes UK
  • Macular Society
Professional groups • Royal College of Physicians
Comparator companies • Alimera (fluocinolone acetonide intravitreal implant) (confidentiality agreement not signed, not participating)
  • Bayer (aflibercept)
  • Genus Pharmaceuticals (bevacizumab) name (confidentiality agreement not signed, not participating)
  • Novartis Pharmaceuticals (ranibizumab)
  • Organon Pharma (bevacizumab) (confidentiality agreement not signed, not participating)
  • Pfizer (bevacizumab) (confidentiality agreement not signed, not participating)
  • Roche (bevacizumab)
  • Sanofi (aflibercept) (confidentiality agreement not signed, not participating)
  • Zentiva (bevacizumab) (confidentiality agreement not signed, not participating)
General commentators • All Wales Therapeutics and Toxicology Centre
  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Scottish Medicines Consortium
  • Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
25 October 2021 Invitation to participate
22 September 2021 - 08 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 September 2021 Following the decision taken to part-review and part-reissue NICE Technology Appraisal Guidance No.349 Dexamethasone intravitreal implant for treating diabetic macular oedema, I am writing to inform you of the draft timelines that we have planned for your information. The appraisal is expected to start during September 2021 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during October 2021. The deadline for submissions is expected in approximately early January 2022.

For further information on our processes and methods, please see our CHTE processes and methods manual